Thymosin Alpha-1
Thymosin Alpha-1 (Tα1)
A 28-amino acid thymic peptide and one of the most clinically validated immune-modulating peptides available. FDA-approved in some countries for hepatitis B/C and used globally as an immune adjuvant in cancer, chronic infection, and immunodeficiency.
Mechanism of Action
Thymosin Alpha-1 is a naturally occurring thymic hormone that acts on dendritic cells, T-lymphocytes, and NK cells. It upregulates MHC class I and II expression, enhances Th1 cytokine production (IL-2, IFN-γ), promotes T-cell maturation and differentiation, and activates toll-like receptor (TLR) signaling pathways. It also suppresses regulatory T-cell (Treg) overactivation that dampens anti-tumor and anti-viral immunity. In chronic infections and cancer, it restores exhausted T-cell function and enhances vaccine immunogenicity.
Health Claims & Evidence
Enhances T-cell and NK cell immunity against viral infections
Improves outcomes in sepsis and critical illness
Augments vaccine immunogenicity in immunocompromised patients
Anti-tumor immune activation and adjuvant to cancer therapy
Restores immune function in chronic fatigue and post-viral syndromes
Reduces susceptibility to opportunistic infections in immunosuppressed patients
Short-Term Effects
Improved energy, reduced infection frequency, enhanced response to vaccines, improved sense of well-being.
Long-Term Effects
Sustained immune competence, reduced viral reactivation, improved cancer surveillance, potential anti-aging immune benefits.
Side Effects
Exceptionally well-tolerated. Rare: mild injection site reactions. No significant systemic adverse effects in decades of clinical use.
Contraindications
Caution in organ transplant recipients (immune stimulation may increase rejection risk). Avoid during active autoimmune flares without specialist supervision.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Thymosin alpha 1 reduces the mortality of severe sepsis by restoring immunity
Liu F et al. · Critical Care Medicine · 2013
Thymosin alpha-1 as an immunomodulatory agent in cancer treatment
Garaci E et al. · Annals of the New York Academy of Sciences · 2012
Clinical use of thymosin alpha-1 in hepatitis B and C
Andreone P et al. · Journal of Viral Hepatitis · 2001
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Thymosin Alpha-1 and related peptides, and prepare an educational research summary.
Explore Research